These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 28336368)
1. Novel strategies in the oral delivery of antidiabetic peptide drugs - Insulin, GLP 1 and its analogs. Ismail R; Csóka I Eur J Pharm Biopharm; 2017 Jun; 115():257-267. PubMed ID: 28336368 [TBL] [Abstract][Full Text] [Related]
2. New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs. Pinto SFT; Santos HA; Sarmento BFCC Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1952. PubMed ID: 38500351 [TBL] [Abstract][Full Text] [Related]
3. Oral delivery of therapeutic protein/peptide for diabetes--future perspectives. Rekha MR; Sharma CP Int J Pharm; 2013 Jan; 440(1):48-62. PubMed ID: 22503954 [TBL] [Abstract][Full Text] [Related]
4. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Jendle J; Martin SA; Milicevic Z Expert Opin Investig Drugs; 2012 Oct; 21(10):1463-74. PubMed ID: 22799463 [TBL] [Abstract][Full Text] [Related]
5. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308 [TBL] [Abstract][Full Text] [Related]
6. Peptide drug delivery strategies for the treatment of diabetes. Sadrzadeh N; Glembourtt MJ; Stevenson CL J Pharm Sci; 2007 Aug; 96(8):1925-54. PubMed ID: 17286287 [TBL] [Abstract][Full Text] [Related]
7. Oral delivery of peptide drugs: barriers and developments. Hamman JH; Enslin GM; Kotzé AF BioDrugs; 2005; 19(3):165-77. PubMed ID: 15984901 [TBL] [Abstract][Full Text] [Related]
8. A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1. Qu W; Li Y; Hovgaard L; Li S; Dai W; Wang J; Zhang X; Zhang Q Int J Nanomedicine; 2012; 7():4983-94. PubMed ID: 23028226 [TBL] [Abstract][Full Text] [Related]
9. Oral delivery of therapeutic proteins and peptides: a review on recent developments. Gupta S; Jain A; Chakraborty M; Sahni JK; Ali J; Dang S Drug Deliv; 2013 Aug; 20(6):237-46. PubMed ID: 23869787 [TBL] [Abstract][Full Text] [Related]
10. Novel delivery technologies for protein and peptide therapeutics. Kumar TR; Soppimath K; Nachaegari SK Curr Pharm Biotechnol; 2006 Aug; 7(4):261-76. PubMed ID: 16918403 [TBL] [Abstract][Full Text] [Related]
11. Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Xu Y; De Keersmaecker H; Braeckmans K; De Smedt S; Cani PD; Préat V; Beloqui A Biomaterials; 2020 Oct; 255():120209. PubMed ID: 32580098 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the oral delivery of insulin. Ramesan RM; Sharma CP Recent Pat Drug Deliv Formul; 2014; 8(2):155-9. PubMed ID: 24867419 [TBL] [Abstract][Full Text] [Related]
13. Oral insulin delivery: how far are we? Fonte P; Araújo F; Reis S; Sarmento B J Diabetes Sci Technol; 2013 Mar; 7(2):520-31. PubMed ID: 23567010 [TBL] [Abstract][Full Text] [Related]
14. Engineered nanoparticles in non-invasive insulin delivery for precision therapeutics of diabetes. Adwani G; Bharti S; Kumar A Int J Biol Macromol; 2024 Aug; 275(Pt 1):133437. PubMed ID: 38944087 [TBL] [Abstract][Full Text] [Related]
15. Nanotechnology as a promising strategy for alternative routes of insulin delivery. Reis CP; Damgé C Methods Enzymol; 2012; 508():271-94. PubMed ID: 22449931 [TBL] [Abstract][Full Text] [Related]